PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Clotiapine→

Clotiapine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2058-52-8
Molecular formula
C18H18ClN3S
Molecular weight
343.9 g/mol
Drug class
Dibenzothiazepine antipsychoticdopamine D2 receptor antagonist
Mechanism of action
Antagonises central dopamine D2 receptors and also interacts with serotonin, histamine and adrenergic receptors, reducing psychotic symptoms and contributing to sedative effects.
Indications / reported uses
  • Treatment of acute psychotic disorders and schizophrenia in countries where clotiapine remains authorised; current availability and specific indications are jurisdiction-specific

Sources: NLM MeSH — Clotiapine · PubMed — Clotiapine antipsychotic pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Clotiapine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Clotiapine Permitted Daily Exposure (PDE) report (the Clotiapine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Clotiapine Occupational Exposure Limit (OEL) report (the Clotiapine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.